Abstract:Introduction: Hyperglycemia-induced endothelial cell injury is one of the main causes of diabetic vasculopathy. Fat mass and obesity-associated protein (FTO) was the first RNA N6-methyladenosine (m6A) demethylase identified; it participates in the pathogenesis of diabetes. However, the role of FTO in hyperglycemia-induced vascular endothelial cell injury remains unclear. Materials and methods: The effects of FTO on cellular m6A, autophagy, oxidative stress, proliferation, and cytotoxicity were explored in human umbilical vein endothelial cells (HUVECs) treated with high glucose (33.3 mmol/mL) after overexpression or pharmacological inhibition of FTO. MeRIP-qPCR and RNA stability assays were used to explore the molecular mechanisms by which FTO regulates autophagy. Results: High glucose treatment increased m6A levels and reduced FTO protein expression in HUVECs. Wild-type overexpression of FTO markedly inhibited reactive oxygen species generation by promoting autophagy, increasing endothelial cell proliferation, and decreasing the cytotoxicity of high glucose concentrations. The pharmacological inhibition of FTO showed the opposite results. Mechanistically, we identified Unc-51-like kinase 1 (ULK1), a gene responsible for autophagosome formation, as a downstream target of FTO-mediated m6A modification. FTO overexpression demethylated ULK1 mRNA and inhibited its degradation in an m6A-YTHDF2-dependent manner, leading to autophagy activation. Conclusions: Our study demonstrates the functional importance of FTO-mediated m6A modification in alleviating endothelial cell injury under high glucose conditions and indicates that FTO may be a novel therapeutic target for diabetic vascular complications.

FTO regulates ocular angiogenesis via m6A-YTHDF2-dependent mechanism

FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m 6 A modifications of multiple pro-angiogenic factors

FTO Elicits Tumor Neovascularization in Cancer-Associated Fibroblasts Through Eliminating M6a Modifications of Multiple Pro-Angiogenic Factors

SPI1-induced Downregulation of FTO Promotes GBM Progression by Regulating Pri-Mir-10a Processing in an M6a-Dependent Manner

FTO regulates adipogenesis by controlling cell cycle progression via mA-YTHDF2 dependent mechanism.

N6-Methyladenosine Demethylase FTO Controlsmacrophage Homeostasis in Diabetic Vasculopathy

Lactylation-driven FTO-mediated m6A modification of CDK2 aggravates diabetic microvascular anomalies

Comprehensive analysis of the m6A demethylase FTO in endothelial dysfunction by MeRIP sequencing

Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy

N6-methyladenosine demethylase fat mass and obesity-associated protein suppresses hyperglycemia-induced endothelial cell injury by inhibiting reactive oxygen species formation via autophagy promotion

FTO Fuels Diabetes-Induced Vascular Endothelial Dysfunction Associated with Inflammation by Erasing M6a Methylation of TNIP1.

The RNA N6-methyladenosine demethylase FTO regulates ATG5 to inhibit malignant progression of uveal melanoma

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner

m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer

The m6A Demethylase FTO Promotes Esophageal Cancer Progression Through YTHDF1-Dependent Posttranscriptional Silencing of AKT3

N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1 alpha signalling axis

N6-methyladenosine demethylase FTO regulates inflammatory cytokine secretion and tight junctions in retinal pigment epithelium cells

FTO regulates myoblast proliferation by controlling CCND1 expression in an m6A-YTHDF2-dependent manner

FTO Promotes Clear Cell Renal Cell Carcinoma Progression Via Upregulation of PDK1 Through an M6a Dependent Pathway

N6-methyladenosine Demethyltransferase FTO Mediated M6a Modification of Estrogen Receptor Alpha in Non-Small Cell Lung Cancer Tumorigenesis

N 6 -methyladenosine demethyltransferase FTO mediated m 6 A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis